<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1813">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05137561</url>
  </required_header>
  <id_info>
    <org_study_id>NK/7840/MD/624</org_study_id>
    <nct_id>NCT05137561</nct_id>
  </id_info>
  <brief_title>Robotic-arm Assisted 68 Ga PSMA PET/CT Guided Prostate Biopsy Versus MR Directed TRUS Guided Prostate Biopsy</brief_title>
  <acronym>PROBIOP</acronym>
  <official_title>Comparison of Robotic-arm Assisted 68 Ga PSMA PET/CT Guided Prostate Biopsy Versus MR Directed TRUS Guided (Cognitive Fusion) Prostate Biopsy: A Pilot Study to Assess Diagnostic Performance and Patient Safety</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Postgraduate Institute of Medical Education and Research</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Postgraduate Institute of Medical Education and Research</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The present study aimed to compare the diagnostic accuracy, radiation exposure, complication&#xD;
      rates between 68Ga-PSMA PET/CT guided robotic arm assisted prostate biopsy and MRI directed&#xD;
      TRUS guided prostate biopsy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To compare the diagnostic yield of Robotic-arm assisted 68Ga PSMA PET/CT guided prostate&#xD;
      biopsy and MRI directed TRUS guided prostate biopsy in patients with PIRADS grading 4/5.&#xD;
&#xD;
      To compare the visual pain index of the patients between two arms during the procedure.&#xD;
&#xD;
      To compare the complication rates between the two arms during and after the procedure for a&#xD;
      period of 2 weeks&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 25, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">October 31, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>Simple randomization using RRApp</intervention_model_description>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Diagnostic yield of mpMRI directed vs PET/CT directed prostate biopsy</measure>
    <time_frame>12 months</time_frame>
    <description>The number of participants (with percentages) in whom the biopsy procedure yielded a tissue specimen adequate for a definite pathological diagnosis will be tabulated.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Diagnostic performance of mpMRI directed vs PET/CT directed prostate biopsy</measure>
    <time_frame>12 months</time_frame>
    <description>The sensitivity, specificity and accuracy of mpMR directed TRUS guided (cognitive fusion) and PSMA PET/CT directed biopsy will be compared.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of procedure related complications</measure>
    <time_frame>three months</time_frame>
    <description>The procedure-related complications in the number and percentage of recruiting participants will be tabulated.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Prostate Cancer</condition>
  <condition>Prostate Neoplasm</condition>
  <arm_group>
    <arm_group_label>PSMA PET/CT guided biopsy arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>PSMA PET/CT guided biopsy will be done from PSMA avid lesion of the prostate after reviewing the whole body PSMA PET/CT scan.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MRI directed TRUS guided biopsy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The MRI-directed transrectal ultrasound-guided per-rectal prostate biopsy will be done by cognitive fusion.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>PSMA PET guided prostate biopsy</intervention_name>
    <description>PSMA PET-guided prostate biopsy from PSMA avid prostatic lesion will be done.</description>
    <arm_group_label>PSMA PET/CT guided biopsy arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>MRI directed TRUS guided prostate biopsy</intervention_name>
    <description>TRUS guided MR directed Cognitive fusion prostate biopsy based on the PIRADS scoring</description>
    <arm_group_label>MRI directed TRUS guided biopsy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. PIRADS 4 and 5 prostate lesions and PIRADS &lt;/= 3 prostate lesions with high clinical&#xD;
             suspicion.&#xD;
&#xD;
          2. Patients who are included in the study will be randomly allocated into either PSMA&#xD;
             PET/CT guided biopsy or TRUS guided biopsy using simple randomization in RRApp&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients with acute prostatitis/ urine culture positive.&#xD;
&#xD;
          2. Patients with pre-existing bleeding diathesis like hemophilia, coagulopathy defined by&#xD;
             INR ≥ 1.2, and Platelet counts ≤ 80,000/mm3&#xD;
&#xD;
          3. Patients who refuse to provide the written informed consent&#xD;
&#xD;
          4. Non-cooperative patients&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Prostate cancer is malignancy of the male prostate.</gender_description>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>PGIMER</name>
      <address>
        <city>Chandigarh</city>
        <state>Chandīgarh</state>
        <zip>160012</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rajender Kumar, MD</last_name>
      <phone>+91-9216605341</phone>
      <email>drrajender2010@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Aravindh Ramalingam, MBBS</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>October 26, 2021</study_first_submitted>
  <study_first_submitted_qc>November 27, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 30, 2021</study_first_posted>
  <last_update_submitted>November 27, 2021</last_update_submitted>
  <last_update_submitted_qc>November 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 30, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Postgraduate Institute of Medical Education and Research</investigator_affiliation>
    <investigator_full_name>Rajender Kumar</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_info_type>Study Protocol</ipd_info_type>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

